01—Abstract
Summary
Summary of the 8-K filed August 18, 2025. Cited figures are marked; the original filing is the authoritative source.
Veeva Systems Inc. (VEEV) disclosed in an Item 7.01 Regulation FD filing dated August 18, 2025 that on August 13, 2025 it entered into a settlement agreement with IQVIA Inc. that resolves all ongoing litigation between the two companies, which dated back to 2017.
Under the settlement, neither party will pay damages to the other, and both parties will dismiss with prejudice all pending claims and counterclaims. The companies also entered into agreements to facilitate access to each other's data and software so they can provide certain products and services to mutual customers. Veeva disclosed that it will make a one-time payment of approximately $31 milliona to law firms that represented it in the IQVIA litigation, under previously disclosed outcome-based fee arrangements.
This payment is the only specific financial figure in the filing, and the filing does not quantify any other financial effect of the settlement. The accompanying press release, Exhibit 99.1, announces long-term commercial and clinical partnerships. Commercial terms include master data and software third-party access agreements covering use of IQVIA data in Veeva Network, Veeva Nitro and Veeva AI, and IQVIA joining Veeva's partner programs.
Clinical terms include IQVIA joining Veeva's CRO Clinical Data Partner program to execute trials using Veeva software, including EDC. The information is furnished, not filed, under Section 18 of the Exchange Act.
02—Key points
Key Highlights
- Veeva and IQVIA entered into a settlement agreement on August 13, 2025 that resolves all ongoing litigation between them, which began in 2017.
- Neither party will pay damages to the other, and all pending claims and counterclaims will be dismissed with prejudice.
- Veeva will make a one-time payment of approximately $31 million to law firms that represented it in the litigation, under previously disclosed outcome-based fee arrangements.
- The companies established master data and software third-party access agreements, allowing IQVIA and Veeva data to be used within each other's software in customer instances.
- IQVIA joined Veeva's Technology, AI, and Services Partner Programs and Veeva's CRO Clinical Data Partner program.
- The agreements are described as long-term and global, covering both clinical and commercial offerings.
- The press release and Item 7.01 information are furnished under Regulation FD and are not deemed filed under Section 18 of the Exchange Act.
03—Questions
Frequently Asked Questions
What did Veeva and IQVIA agree to in the August 2025 settlement?
The companies agreed to resolve all ongoing litigation between them, with neither paying damages to the other and both dismissing all pending claims and counterclaims with prejudice. They also entered into agreements to facilitate access to each other's data and software for mutual customers.
How much will Veeva pay as a result of the settlement?
Veeva will make a one-time payment of approximately $31 million to the law firms that represented it in its litigation with IQVIA, under previously disclosed outcome-based fee arrangements.
What partnerships are included in the agreement?
On the commercial side, the companies set up master data and software third-party access agreements, and IQVIA joined Veeva's Technology, AI, and Services Partner Programs. On the clinical side, IQVIA joined Veeva's CRO Clinical Data Partner program and can use Veeva Clinical Suite, including Veeva EDC, to run clinical trials.
Does this filing include a financial impact beyond the $31 million payment?
The filing identifies only the approximately $31 million one-time payment to law firms. It does not quantify other financial effects of the settlement or the partnerships.
04—Continue